CIK 0001994702 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Kyverna Therapeutics, Inc.
Sign in to watch- Ticker
- KYTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831365441
- Phone
- 5109252492
- Business address
- 5980 HORTON STREET, SUITE 200, EMERYVILLE, CA
- Former names
- Kyverna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-24 | Emany Sravan Kumar Director | Grant or award · Stock Option (right to buy) | +42,945 | 42,945 | ||
| 2026-02-09 | Pujols Mayobanex Chief Technology Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2026-01-12 | Shaw Christi Executive Chairperson | Grant or award | +30,000 | 46,634 | ||
| 2026-01-12 | Shaw Christi Executive Chairperson | Grant or award | +24,301 | 70,935 | ||
| 2026-01-12 | Shaw Christi Executive Chairperson | Grant or award · Stock Option (right to buy) | +185,000 | 185,000 | ||
| 2025-12-18 | SEIDENBERG BETH C Director | Purchase | +133,333 | $7.50 | $1000K | 869,317 |
| 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. 10% owner | Purchase | +133,333 | $7.50 | $1000K | 869,317 |
| 2025-12-15 | Walker Karen Marie Chief Technology Officer | Option exercise 10b5-1 | +23,998 | $4.83 | $116K | 46,634 |
| 2025-12-15 | Walker Karen Marie Chief Technology Officer | Sale 10b5-1 | −23,998 | $12.20 | $293K | 22,636 |
| 2025-12-15 | Walker Karen Marie Chief Technology Officer | Option exercise · Stock option (right to buy) 10b5-1 | −23,998 | 85,865 | ||
| 2025-06-30 | GRASSO MARC Chief Financial Officer | Grant or award · Stock Option (right to buy) | −450,000 | 450,000 | ||
| 2025-05-29 | Shaw Christi Director | Grant or award | +16,634 | 16,634 | ||
| 2025-05-29 | Shaw Christi Director | Grant or award · Stock Option (right to buy) | +65,351 | 65,351 | ||
| 2025-05-29 | SEIDENBERG BETH C Director | Grant or award | +16,634 | 16,634 | ||
| 2025-05-29 | SEIDENBERG BETH C Director | Grant or award · Stock Option (right to buy) | +65,351 | 65,351 | ||
| 2025-05-29 | SPIEGELMAN DANIEL K Director | Grant or award | +16,634 | 16,634 | ||
| 2025-05-29 | SPIEGELMAN DANIEL K Director | Grant or award · Stock Option (right to buy) | +65,351 | 65,351 | ||
| 2025-05-29 | Aktar Mert Director | Grant or award | +16,634 | 16,634 | ||
| 2025-05-29 | Aktar Mert Director | Grant or award · Stock Option (right to buy) | +65,351 | 65,351 | ||
| 2025-05-29 | CLARK IAN T Director | Grant or award | +16,634 | 16,634 |
Page 2 of 5 · 91 trades